TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3219542

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at 10 pm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy (HSV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31983236

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17160
Study: 31291514

Group type: EXPERIMENTAL
Intervention: CRP-guided group (usual care guided by CRP point-of-care testing)
Number of subjects: 653

Group type: COMPARATOR
Intervention: Usual-care group (usual care alone)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: CRP-guided group
Number of subjects: 653

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 653
Study: 29101325

Group type: EXPERIMENTAL
Intervention: Positive social feedback from humanoid robot
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-social positive feedback from humanoid robot
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Cognitive flexibility impairment and antipsychotic dosing
Number of subjects: 44
Study: 25861013

Group type: EXPERIMENTAL
Intervention: 10 × 10 RE
Number of subjects: 27

Group type: COMPARATOR
Intervention: 5 × 10 RE
Number of subjects: 27

Group type: COMPARATOR
Intervention: EE
Number of subjects: 27
Study: 23616308

Group type: EXPERIMENTAL
Intervention: Increased self-efficacy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decreased self-efficacy
Number of subjects: 0
Study: 21461325

Group type: EXPERIMENTAL
Intervention: Tongue Stabilizing Device (TSD)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Mandibular Advancement Splint (MAS)
Number of subjects: 39
Study: 18430965

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 300 mg weekly for 16 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 17634176

Group type: EXPERIMENTAL
Intervention: High phytate diet
Number of subjects: 29

Group type: COMPARATOR
Intervention: Low phytate diet
Number of subjects: 29
Study: 12946082

Group type: EXPERIMENTAL
Intervention: Manual-assisted cognitive behaviour therapy (MACT)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Quality of life measures
Number of subjects: 480
Study: 11121913

Group type: COMPARATOR
Intervention: Omeprazole, tinidazole, and clarithromycin for 10 days (group OTC)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Therapy based on the susceptibility test (group SUSC)
Number of subjects: 109
Study: 9545884

Group type: EXPERIMENTAL
Intervention: Fluoride-containing fissure sealant (Helioseal-F)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (no fissure sealants)
Number of subjects: 204
Study: 8362175

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 14

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 14
Study: 3519237

Group type: EXPERIMENTAL
Intervention: oxprenolol + placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: oxprenolol + sulphinpyrazone
Number of subjects: 10

Group type: COMPARATOR
Intervention: oxprenolol
Number of subjects: 10
Study: 29534507

Group type: EXPERIMENTAL
Intervention: CHO mouth rinse
Number of subjects: 9

Group type: COMPARATOR
Intervention: PLA mouth rinse
Number of subjects: 9
Study: 28929932

Group type: EXPERIMENTAL
Intervention: Care costs for patients with hip fractures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-fracture functional status
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hospital costs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preventive programmes and comprehensive geriatric care
Number of subjects: 0
Study: 24922162

Group type: EXPERIMENTAL
Intervention: It's Your Game . . . Keep It Real (IYG)
Number of subjects: 766

Group type: COMPARATOR
Intervention: Control
Number of subjects: 766
Study: 22415409

Group type: EXPERIMENTAL
Intervention: VeinViewer®
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 111
Study: 20647107

Group type: EXPERIMENTAL
Intervention: Vibringe
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Syringe irrigation
Number of subjects: 0
Study: 18562773

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) supplementation (1 g/kg body weight)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 19
Study: 15799734

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% gel topically
Number of subjects: 54

Group type: COMPARATOR
Intervention: Lidocaine 2% solution subconjunctivally
Number of subjects: 54
Study: 12057986

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 1117

Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 1117
Study: 10696399

Group type: EXPERIMENTAL
Intervention: Permethrin-treated chaddars and top-sheets
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo-treated chaddars
Number of subjects: 395
Study: 8712196

Group type: EXPERIMENTAL
Intervention: Multifactorial targeted intervention (TI)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Social visit (SV)
Number of subjects: 301
Study: 1897347

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine 4 ml.h‐1 (BUPI‐group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 mg morphine bolus followed by 0.2 mg.h‐1 (MO‐group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of bupivacaine and morphine (COMB-group)
Number of subjects: 60
Study: 6856079

Group type: EXPERIMENTAL
Intervention: Iohexol (Omnipaque)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meglumine‐Ca‐metrizoate (Isopaque cerebral)
Number of subjects: 0
Study: 30239650

Group type: EXPERIMENTAL
Intervention: Cenicriviroc (dual CCR5/CCR2 antagonist)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: CCR5 delta-32 allele
Number of subjects: 2

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 2

Group type: COMPARATOR
Intervention: Cenicriviroc (100 mg dose)
Number of subjects: 2
Study: 28144810

Group type: EXPERIMENTAL
Intervention: Prevention group (skill building training program)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 304
Study: 26491109

Group type: EXPERIMENTAL
Intervention: Ticagrelor (pooled doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ticagrelor vs. placebo
Number of subjects: 0
Study: 23030511

Group type: EXPERIMENTAL
Intervention: Long-pulsed Nd:YAG laser (LPNY) treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control site (untreated side)
Number of subjects: 27
Study: 22264573

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pravastatin 80 mg daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both statins
Number of subjects: 36
Study: 20528598

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate and montelukast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17089419

Group type: EXPERIMENTAL
Intervention: Higher weekly contact hours
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Patient ratings of expressed emotion (EE)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: General Health Questionnaire
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Experience of Caregiving Inventory
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Self‐report Family Inventory
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Inventory of Interpersonal Problems
Number of subjects: 112
Study: 16298490

Group type: EXPERIMENTAL
Intervention: Threat-increasing information
Number of subjects: 100

Group type: COMPARATOR
Intervention: No-threat condition (reassuring information)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Focusing on sensory pain sensations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Focusing on affective components of pain
Number of subjects: 100
Study: 11978646

Group type: EXPERIMENTAL
Intervention: Cycle exercise (approximately 70% peak oxygen consumption)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 13

Group type: COMPARATOR
Intervention: Hyperinsulinemic-euglycemic clamps
Number of subjects: 13
Study: 10404908

Group type: EXPERIMENTAL
Intervention: Zanamivir (10 mg once daily for 4 weeks)
Number of subjects: 1107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1107
Study: 7758492

Group type: EXPERIMENTAL
Intervention: Gentamicin 4.5 mg/kg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gentamicin 1.5 mg/kg every eight hours (thrice daily)
Number of subjects: 100
Study: 1691243

Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT) at lower doses (500-600 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapies targeting different viral replicative sites
Number of subjects: 0
Study: 623512

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine hydrochloride (Flexeril)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam (Valium)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30420161

Group type: EXPERIMENTAL
Intervention: benznidazole
Number of subjects: 1508

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1508
Study: 28797349

Group type: EXPERIMENTAL
Intervention: Biomarker-based prediction model (ABC-CHD model) including NT-proBNP, hs-cTnT, low-density lipoprotein cholesterol, age, smoking, diabetes mellitus, and peripheral arterial disease
Number of subjects: 13164

Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 13164

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 13164

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol
Number of subjects: 13164

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 13164
Study: 25497439

Group type: EXPERIMENTAL
Intervention: Minocycline (200mg/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24119112

Group type: EXPERIMENTAL
Intervention: TY 8 mg (bisoprolol transdermal patch)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BO 5 mg (bisoprolol fumarate oral formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TY 8 mg
Number of subjects: 0
Study: 21801451

Group type: EXPERIMENTAL
Intervention: Movement strategy training combined with falls prevention education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progressive resistance strength training combined with falls prevention education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generic life-skills social program
Number of subjects: 0
Study: 19497571

Group type: EXPERIMENTAL
Intervention: Music intervention (listening to favorite music for 30 min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control intervention (listening to a blank disc for 30 min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 60
Study: 16677243

Group type: EXPERIMENTAL
Intervention: Fluticasone (50 microg bid)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Salmeterol (25 microg bid)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combination of Fluticasone and Salmeterol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 15262663

Group type: EXPERIMENTAL
Intervention: Doxycycline, 200 mg daily for 12 months
Number of subjects: 491

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 491
Study: 12359793

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg/d for 2 days, then 0.25 mg/kg/d for 2 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 30
Study: 9695133

Group type: EXPERIMENTAL
Intervention: Lupron injections (GnRH agonist) followed by transdermal estradiol (Patch)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lupron injections (GnRH agonist) followed by resuming menstrual cycles (Cycle)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (Lupron injections only)
Number of subjects: 24
Study: 8567778

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 120 mg/day
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 2475059

Group type: EXPERIMENTAL
Intervention: lactose-free soy formula
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: low-lactose low-fat cow's milk formula
Number of subjects: 100

Group type: COMPARATOR
Intervention: four different oral refeeding regimes
Number of subjects: 100
Study: 873718

Group type: EXPERIMENTAL
Intervention: Ro 8‐1998
Number of subjects: 30

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 30
Study: 29221475

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 16
Study: 26219426

Group type: EXPERIMENTAL
Intervention: Religiously integrated cognitive behavioral therapy (RCBT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard cognitive behavioral therapy (SCBT)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Higher baseline religiosity
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Higher baseline optimism
Number of subjects: 132
Study: 23336668

Group type: EXPERIMENTAL
Intervention: Glimepiride/metformin sustained release (GM-SR) 2/500 mg once daily
Number of subjects: 207

Group type: COMPARATOR
Intervention: Glimepiride/metformin (GM) 1/250 mg twice daily
Number of subjects: 207
Study: 21330239

Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent (BES) with biodegradable polymer
Number of subjects: 497

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES) with durable polymer
Number of subjects: 497
Study: 18926655

Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic biliary drainage (PTBD)
Number of subjects: 419
Study: 16894414

Group type: EXPERIMENTAL
Intervention: Salivary gland scintigraphy (SGS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Salivary gland ultrasonography (SUS)
Number of subjects: 20
Study: 15073257

Group type: EXPERIMENTAL
Intervention: (188)Re-HDD/lipiodol therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: (131)I-lipiodol therapy
Number of subjects: 23
Study: 11468763

Group type: EXPERIMENTAL
Intervention: Cumulative logit models for ordinal data analysis using longitudinal allergy data.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian approach to modeling.
Number of subjects: 0
Study: 9565408

Group type: EXPERIMENTAL
Intervention: Tailored written feedback based on chart reviews and relevant articles sent to intervention group (n=72) during a 3-month period.
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (n=75) received no tailored feedback.
Number of subjects: 147
Study: 29996359

Group type: EXPERIMENTAL
Intervention: Resin-based sealant (Group R)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Glass ionomer sealant (Group G)
Number of subjects: 419

Group type: COMPARATOR
Intervention: None (Control Group N)
Number of subjects: 419
Study: 28704625

Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulation (SM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 24
Study: 26524571

Group type: EXPERIMENTAL
Intervention: Acupuncture sessions (12 sessions, 600 minutes total) plus usual care
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Alexander Technique lessons (20 lessons, 600 minutes total) plus usual care
Number of subjects: 517

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Both interventions (Acupuncture and Alexander lessons)
Number of subjects: 517
Study: 23331486

Group type: EXPERIMENTAL
Intervention: Intervention practices providing comprehensive health assessments and referrals to care facilities.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care provided by control practices.
Number of subjects: 24
Study: 19781238

Group type: EXPERIMENTAL
Intervention: Open Nirschl procedure
Number of subjects: 26

Group type: COMPARATOR
Intervention: Arthroscopic Nirschl procedure
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 26
Study: 17347294

Group type: EXPERIMENTAL
Intervention: Ultrasonic cleaning for 15 minutes
Number of subjects: 32

Group type: COMPARATOR
Intervention: No decontamination (control)
Number of subjects: 32
Study: 15078725

Group type: EXPERIMENTAL
Intervention: Dobutamine (10 micro g/kg/min for 8 h every 14 days) + oral amiodarone (400 mg/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo + oral amiodarone (400 mg/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (Dobutamine and Placebo)
Number of subjects: 30
Study: 11427359

Group type: EXPERIMENTAL
Intervention: Film-coated placebo risedronate tablet (oval)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Uncoated placebo tablet (round)
Number of subjects: 28
Study: 9673606

Group type: EXPERIMENTAL
Intervention: Comprehensive preconception risk assessment and referral to primary care services
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual care group (no feedback provided)
Number of subjects: 170
Study: 8018438

Group type: EXPERIMENTAL
Intervention: Psychoeducational (PE) program
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard information (INFO) condition
Number of subjects: 152
Study: 2700320

Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg twice daily for 15 days, then 40 mg twice daily for 45 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Atenolol 100 mg once daily for 60 days
Number of subjects: 60
Study: 765382

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (100 mug 4 times daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 42
Study: 31038038

Group type: EXPERIMENTAL
Intervention: Creative interventions for symptoms of postnatal depression
Number of subjects: 91
Study: 27721190

Group type: EXPERIMENTAL
Intervention: Behavioral activation for depression via telemedicine
Number of subjects: 241

Group type: COMPARATOR
Intervention: Behavioral activation for depression via same-room treatment
Number of subjects: 241
Study: 26125257

Group type: COMPARATOR
Intervention: Nimodipine (group A)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Infrared polarized light therapy (group B)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Botulinum toxin treatment (group C)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Joint treatment (group D)
Number of subjects: 91
Study: 23164310

Group type: COMPARATOR
Intervention: Watching a DVD for 30 minutes
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Playing with blocks for 30 minutes
Number of subjects: 49
Study: 21704968

Group type: EXPERIMENTAL
Intervention: Figure-of-eight closure (group A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sternal weave closure (group B)
Number of subjects: 150
Study: 19652565

Group type: EXPERIMENTAL
Intervention: PLL removed
Number of subjects: 58

Group type: COMPARATOR
Intervention: PLL preserved
Number of subjects: 58
Study: 17607002

Group type: EXPERIMENTAL
Intervention: Environmental tobacco smoke
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ozone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endotoxin
Number of subjects: 0
Study: 15510795

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (not specified what treatment)
Number of subjects: 72
Study: 11555566

Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin plus standard CF care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus standard CF care
Number of subjects: 0
Study: 9626184

Group type: EXPERIMENTAL
Intervention: Hypothermia (32 degrees C)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Normothermia (37 degrees C)
Number of subjects: 39
Study: 7884789

Group type: EXPERIMENTAL
Intervention: Doxazosin (4.5 +/- 2.9 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Enalapril (12.5 +/- 6.5 mg/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 44
Study: 2905254

Group type: EXPERIMENTAL
Intervention: roxatidine acetate 75 mg twice a day for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: roxatidine acetate 75 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: roxatidine acetate 150 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 31847705

Group type: EXPERIMENTAL
Intervention: Emotional faces during response compatible trials (low conflict)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional faces during response incompatible trials (high conflict)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized conflict and emotion conditions across Experiments 2, 3, and 4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictability of compatibility and emotion
Number of subjects: 0
Study: 31472811

Group type: EXPERIMENTAL
Intervention: Evidence-based multifaceted intervention including automated identification of patients at increased risk for CI-AKI, point-of-care information on safe contrast volume targets, personalized recommendations for hemodynamic optimization of intravenous fluids, and follow-up information for patients at risk.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 31
Study: 28887511

Group type: EXPERIMENTAL
Intervention: Hemoglobin level as a prognostic factor
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Prognostic nomogram including hemoglobin
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: C-index of the model
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Random survival forest (RSF) classifier
Number of subjects: 192